Parks Katherine, Diebold Kendall, Salzman Donna, Di Stasi Antonio, Al-Kadhimi Zaid, Espinoza-Gutarra Manuel, Bhatia Ravi, Jamy Omer
Department of Internal Medicine University of Alabama at Birmingham Birmingham Alabama USA.
Department of Medicine Division of Hematology and Oncology University of Alabama at Birmingham Birmingham Alabama USA.
EJHaem. 2024 May 15;5(3):560-564. doi: 10.1002/jha2.915. eCollection 2024 Jun.
Relapse remains a major cause of treatment failure following allogeneic stem cell transplantation (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We retrospectively investigated low-dose decitabine and venetoclax (DEC/VEN) as post-transplant maintenance in 26 older patients with AML and MDS. The cumulative incidence of day 100 gIII-IV acute graft versus host disease (GVHD) and 1-year moderate-severe chronic GVHD was 5% and 26%, respectively. One patient relapsed 14 m after transplant. The 1-year non-relapse mortality and survival were 11% and 84%, respectively. DEC/VEN is a safe and potentially effective strategy to reduce the risk of post-transplant relapse.
对于急性髓系白血病（AML）和骨髓增生异常综合征（MDS）患者，复发仍然是异基因干细胞移植（allo-SCT）后治疗失败的主要原因。我们回顾性研究了低剂量地西他滨和维奈克拉（DEC/VEN）作为26例老年AML和MDS患者移植后维持治疗的情况。移植后100天III-IV级急性移植物抗宿主病（GVHD）和1年中重度慢性GVHD的累积发生率分别为5%和26%。1例患者在移植后14个月复发。1年无复发生存率和总生存率分别为11%和84%。DEC/VEN是一种安全且可能有效的降低移植后复发风险的策略。
